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ABSTRACT
Diverse strategies to develop novel treatments
for rheumatoid arthritis which specifically
target those patients who do not respond to
available medications, including biologics, are
currently being explored. New potential
therapeutic approaches which may become
available as part of standard therapeutic
regimens include the propagation of
regulatory T cells and—in the future—of
regulatory B cells. New biologic
disease-modifying antirheumatic drugs
(b-DMARDs) against interleukin-17 and -6,
granulocyte-macrophage colony-stimulating
factor, and complement component 5 are now
standard components of clinical treatment
programs. In addition, recent data indicate
that bispecific monoclonal antibody therapies
may be more effective than monoclonal
antibody monotherapies. It is also becoming
apparent that the use of more toxic b-DMARDs
against B cells, a therapeutic strategy already
being applied in the treatment of hematological
diseases, may also be efficacious for treating B
cell-mediated autoimmune diseases.
Undoubtedly, more small molecules will be
developed in the future, and combination
therapies with, for example, kinase inhibitors
and b-DMARDs, will most likely be tested.
Finally, immunoproteasome inhibitors will
become available for patients with B
cell-mediated autoimmunities, which are
refractory to currently available treatment
options. The new and exciting extension of
current treatment options for rheumatoid
arthritis, biosimilars, will not be discussed in
this review as details on these agents are
available in recently published reports.
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INTRODUCTION
The introduction of new biologic
disease-modifying antirheumatic drugs
(b-DMARDs) has without any doubt
significantly expanded the treatment options
for rheumatoid arthritis (RA) patients over the
past two decades. However, the b-DMARDS
currently available for treating RA patients
show clinical efficacy only in about two-thirds
of RA patients. In addition, some RA patients
show only a partial response to treatment with
b-DMARDs, and biologics are contraindicated
for others. Thus, there is an obvious need to
define new targets and to develop new
treatment principles. Three major therapeutic
avenues are discussed in this review: the
activation of regulatory T cells (Tregs) or
regulatory B cells (Bregs), the development of
new monoclonal and bispecific monoclonal
antibodies and, finally, new small molecules.
Specifically emerging therapies for RA which
are already used in clinical practice or which
will become available in the new future are
addressed. Biosimilars, the new and exciting
extension of current treatment options for RA,
will not be discussed in this review as these
molecules have been discussed in very recent
publications. This article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
IMMUNE MODULATION BY TREGS
Regulatory T cells are defined as a subgroup of
naı¨ve CD4 helper T cells. They can be divided
into natural Tregs (N-Tregs), which originate in
the thymus, and induced Tregs (i-Tregs), which
are propagated in peripheral lymphoid organs.
Tregs are characterized by the expression of the
transcription factor forkhead box protein P3
(Foxp3) and the surface molecule CD25.
N-Tregs can be activated by interleukin-2
(IL-2), and i-Tregs are activated and expanded
by either IL-2, IL-10, or transforming growth
factor beta (TGFb). An important function of
Tregs is to maintain the immune homeostasis
and tolerance of the host, and its main mode of
action occurs via the secretion of IL-10 and
TGFb. With regard to function and phenotypic
patterns, Tregs are not a homogeneous
population [1–4].
The importance of Tregs in RA is
underscored in a number of recent
publications. It has been shown that the
compromised function of Tregs T-cells in RA
patients can be normalized by anti-tumor
necrosis factor-alpha (TNFa) therapy [5] and
that adalimumab—but not etanercept—induces
a stable Treg cell population that has the
potential to restrain the progression of
IL-17-associated inflammation in RA via the
regulation of monocyte-derived IL-6 [6]. Not
only CD4-positive (CD?) Tregs, but also CD8/
Foxp3-positive (CD8?Foxp3?) Tregs have been
described in RA patients. These cells can be
induced by anti-CD3 monoclonal antibody and
could be combined with a p38 inhibitor to
improve therapeutic efficacy by resolving
chronic inflammation via the restoration of
tolerance. However, more data are needed to
determine whether this activation of CD8?
Tregs is a potentially valuable approach for
treating autoimmune diseases including RA [7].
In vitro studies on the CD28 superagonist
TGN14112/TABQ8 monoclonal antibody have
been conducted [8–10]. When this monoclonal
antibody was tested in dilutions ranging from 1
to 0.6 lg/ml on peripheral blood mononuclear
cells (PBMCs) from RA patients, an expansion of
Tregs was noted which was paralleled by an
increase in IL-10 levels. When it was applied at
32 Rheumatol Ther (2016) 3:31–42
low doses to healthy volunteers, the Treg
signature cytokine IL-10 was released in a
dose-dependent manner in the absence of any
production of proinflammatory factors [8–10].
These data contrast markedly with the results
obtained when the CD28 superagonistic
monoclonal antibody was administered at
significantly higher doses to volunteers, with
the latter developing a cytokine release
syndrome [11, 12]. This superagonistic
antibody is currently being tested in clinical
trials in RA patients. To date, no severe side
effects have been reported.
Deregulated expression of microRNA
(miR)-146a and miR-155 has been associated
with RA. When both of these microRNAs were
studied with regard to their possible impact on
Treg function, only miR-146a facilitated a
proinflammatory phenotype of Treg via an
increased activation of the transcription factor
STAT1, thereby contributing to RA pathogenesis
[13]. This finding opens the possibility to use an
antagomir in those patients with this abnormal
Treg phenotype. Antagomirs are a class of
chemically engineered oligonucleotides which
silence endogenous microRNAs.
Although the use of propagated Tregs to treat
RA patients seems to be very promising, further
trials are needed to definitively prove that this
treatment option has the potential to be a new
and efficacious treatment alternative with
acceptable side effects.
NEW B-DMARDS
b-DMARDs Targeting IL-17A and IL-17R
Secukinumab has been approved by the Federal
Drug Administration as a treatment for
psoriasis, and approval is pending for psoriatic
arthritis (PsA). Its efficacy has also been shown
for the treatment of ankylosing spondylitis AS
and RA. However, in RA only long-term
treatment with secukinumab was associated
with an improvement of signs and symptoms.
More clinical data are clearly necessary to be
able to reliably assess the role of blocking IL-17
A as a treatment principle for RA. Ixekizumab
(Taltz) has been shown to improve signs and
symptoms of RA patients. In contrast, the
human monoclonal antibody brodalumab did
not show clinical efficacy in RA. In summary, it
appears that the clinical signs and symptoms of
psoriasis, PsA, and As in particular can be
significantly improved in patients receiving
b-DMARDs which target either IL-17A or the
IL-17 receptor. However, for patients with RA,
the clinical efficacy of this class of b-DMARDs
seems to be lower than that of the TNFa blocker
[14–17]. The safety profile of these new
b-DMARDs is similar to that observed with
other biological agents.
b-DMARDs Targeting IL-6 and the IL-6
Receptor
The first report on the use of an monoclonal
antibody against IL-6 was published by
Wendling et al. in 1993 [18]. After this first
trial it took some time until toxilizumab came
on the market, which, in contrast to other
b-DMARDs introduced up to then, turned out to
be an efficacious alternative treatment option in
RA. Since then, quite a number of monoclonal
antibodies directed against IL-6 or the IL-6
receptor have been tested in clinical trials,
including sirukumab, olokizumab, sarilumab,
and clazakizumab. Data from phase I to phase
III trials are similar and consistent with those
observed with toxilizumab [19–21]. The clinical
efficacy of these b-DMARDs appears to be
similar to that of TNFa blockers in patients
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with the methotrexate (MTX-RI) or the TNFa
receptor (TNFa-RI). Side effects include upper
and lower respiratory tract infections,
neutropenia, elevated enzyme levels
determined in liver function tests, and
elevated total cholesterol and are similar to
those observed with toxilizumab [22].
Five b-DMARDs targeting IL-6 or the IL-6
receptor may soon be on the market, raising
the following questions: Do we need six
biologics targeting IL-6? How should these
different anti-IL-6-directed b-DMARDs be
used? Can they be used interchangeably such
that a patient can be switched from one to the
other if the first one does not show clinical
efficacy? Might there be specific subgroups of
patients who respond to one or the other IL-6
inhibitor preferentially? Might there be
differences in long-term treatment with the
different IL-6 blocking agents in terms of side
effect profiles, clinical efficacy, or effect on
structural damage and long-term outcome [22].
From the results available to date, it would
appear that there are no major differences
between these d-DMARDS targeting IL-6 or
the IL-6 receptor in terms of inducing an
improvement in clinical signs and symptoms
and side effect profiles.
b-DMARDs Targeting IL-20
Interleukin-20 seems to be an interesting target
for immune intervention in RA. IL-20 was
found to be overexpressed in the synovial fluid
of RA patients versus patients with
osteoarthritis (OA), and IL-20 and its receptors
were seen to be consistently expressed in the
synovial membranes of synovial fibroblasts [23].
These results indicate that IL-20 is involved in
RA, especially in local inflammation. IL-20 was
found to induce the proliferation of endothelial
cells. It may be involved in angiogenesis, as
shown in the synovial membrane of RA
patients, and it may also play a role in
angiogenesis [23]. Based on this experimental
data, IL-20 blockers have been used in a
collagen-induced arthritis rat model as
monotherapy or in combination therapy with
etanercept (Enbrel). The data from these studies
clearly show that in vivo treatment with the
anti-IL-20 monoclonal antibody alone or in
combination with etanercept significantly
reduces the severity of arthritis by decreasing
hind paw thickness and swelling, preventing
cartilage damage and bone loss, and reducing
the expression of IL-20, IL-1b, and IL-6 [24].
Available data suggest that IL-20 indeed might
be a valuable target for immune intervention in
RA patients, specifically when bispecific
monoclonals are developed which target both
IL-20 and TNFa.
EULAR recommendations for the use of
biologics in RA clearly state that in all treatments
biologics should be combined preferentially with
MTX or, if there are contraindications, with other
immunosuppressive agents [25]. This also includes
treatment with tocilizumab which shows an
increased clinical efficacy when given as a
monotherapy as compared to when given as
biotherapy with TNFa blockers [26]. In patients
not showing significant response to MTX, the
inclusion of tocilizumab as an add-on treatment
wasobservedtosignificantly improve thesignsand
symptoms of RA, as well as to slow down
radiological progression [27].
b-DMARDs Targeting CM-CSF
Di Franco et al. [28] recently discussed evidence
supporting the development of treatments
against the GM-CSF receptor in RA. These
authors reported that GM-CSF has a major
impact on the activation, differentiation, and
survival of neutrophils and macrophages. They
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observed increased levels of GM-CSF in synovial
fluid, with GM-CSF exacerbating RA;
furthermore, a reduction of CD68?
macrophages in synovial tissue has been
correlated with improvement in the disease
activity score. Finally, antagonizing GM-CSF
was found to markedly reduce established
disease in mouse models of RA. The proof of
principle that blocking GM-CSF might be a new
treatment option for RA has recently been
published [29, 30]. In these latter studies a
significant increase in the percentage of RA
patients showing a 20 or 50% response rate
according to the guidelines of the American
College of Rheumatology (=an improvement of
20 or 50% in signs and symptoms) was reported
over a period of 24 weeks with 50 up to 100 mg
mavrilimumab given subcutaneously for
12 weeks. However, further studies are
necessary to determine whether this
monoclonal antibody is a real alternative for
patients not responding to treatment with
available b-DMARDS. That GM-CSF itself
might be a useful target for immune
intervention in RA patients has been reported
recently; in this study treatment with a human
monoclonal antibody against GM-CSF was
shown to be efficacious in patients with active
RA [31].
Given the importance of macrophages and
neutrophils for the pathogenesis of RA, one can
only hope that this new b-DMARD will soon be
available for use in daily clinical practice. It is
important that no severe pulmonary side effects
have been observed in completed or ongoing
clinical trials since the epithelium of the
pulmonary mucosa is a major producer of
GM-CSF and GM-CSF plays a critical role
locally in regulating microbial clearance and
surfactant clearance by alveolar macrophages.
b-DMARDs Targeting C5
The burden of evidence supporting the
involvement of complement ) in the
pathogenesis of RA has led to several attempts
to apply drugs inhibiting complement
activation. In this context, C5 constitutes an
ideal pharmacological target: its activation leads
to the release of the proinflammatory peptide
C5a, a mediator involved in various immune
functions, such as chemotaxis, activation of
inflammatory cells, vasopermeability, among
others. C5a is also essential for the assembly of
the terminal membrane attack complex. An
orally active C5a receptor antagonist has been
shown to reduce the severity of synovitis in a rat
model of immune-mediated monoarticular
arthritis [32]. A novel monoclonal anti-C5
antibody, M107, has recently been described
which has a high specificity for the synovial
epithelium. In one study a neutralizing
antibody to C5 was coupled to a peptide
isolated by an in vivo selection from a phage
peptide library [33]. This peptide was found to
target the synovial endothelium from patients
with RA and OA transplanted into SCID (severe
combined immunodeficiency) mice. The
peptide was highly specific, and no binding to
inflamed kidney or lung was demonstrated.
M107 was effective in reducing the disease
severity as revealed by the decrease in joint
swelling and the amelioration of synovitis [33].
More data from animal studies as well as from
phase I/II clinical trials are warranted to
determine whether blocking C5 will be an
efficacious and alternative treatment principle
for RA patients who are or become refractory to
the available treatment options. Based on the
animal model described here, this monoclonal
antibody might be a molecule for intraarticular
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application. The monoclonal anti-C5 antibody
eculizumab has recently been approved for the
treatment of the atypical hemolytic-uremic
syndrome [34].
Bispecific Monoclonal Antibodies
Bispecific monoclonal antibodies are frequently
used to treat cancer, leukemia, and lymphoma.
A new bispecific monoclonal antibody,
anti-CD19/anti-CD3 BITE antibody, has
recently been found to be extremely
efficacious for the treatment of B-cell leukemia
and B-cell lymphoma due to its B-cell deleting
action [35, 36]. Taking into consideration that
the efficacy of rituximab, a monoclonal
antibody, is also mainly due to its B
cell-deleting action, an interesting question is
whether the use of the anti-CD19/anti-CD3
BITE antibody could be extended to the
treatment of autoimmune diseases
characterized by pathogenic autoantibodies,
such as RA or systemic lupus erythematosus,
and specifically for those patients who do not
respond to any other currently available
treatments.
Recent in vitro experiments have
demonstrated that the combined blockade of
TNFa and IL-17 is more efficacious than a single
blockade in terms of inhibiting the release of
chemokines, lymphokines, or matrix enzymes.
In arthritic mice, a bispecific monoclonal
antibody paired on one arm to TNFa and on
the second arm to IL-17 was more efficacious in
inhibiting the development of inflammation
and bone and cartilage destruction than either
TNFa or IL-17 monoclonal antibody alone [37].
The growing interest in developing bispecific
monoclonal antibodies for the treatment of RA
is reflected by the increasing number of
abstracts on this subject at last year’s EULAR
Conference. These include reports on the results
of Phase-I A and Phase -II B trials conducted
using bispecific antibodies against TNFa and
IL-17A [38, 39] and against TNFa and ICAM-1,
respectively [40], as well as data on the use of a
novel dual variable domain immunoglobulin
that specifically neutralizes both TNFa and
IL-17A [41, 42]. The synergistic effect observed
by the dual blockade of TNFa and IL17 as well as
the new upcoming bispecific monoclonal
antibody constructs are worth following up
on, specifically to determine if they could
become valuable treatment principles for RA
patients.
Bispecific antibodies bind to two different
antigens or epitopes on one or two different
molecules at the cell surface. One of the
potential advantages of these antibodies relates
to their avidity. In addition, since in RA the
pathogenesis is multifactorial, it is possible that
a treatment which blocks two proinflammatory
cytokines like TNFa and IL-6 using a bispecific
antibody, or TNFa and IL-17, might be more
efficacious than a treatment which blocks either
IL-17 or TNFa. Finally, during the course of the
disease, new and additional important
pathogenic mechanisms might develop which
could be attacked by bispecific monoclonal
antibodies. The possibilities mentioned here
may explain the known superiority of
bispecific antibodies over monospecific
antibodies for treatment purposes.
Regulatory B Cells
B cells are known primarily for their ability to
produce both antibodies and autoantibodies for
the activation of T cells via antigen
presentation. B cells can also interact with and
activate other cells of the immune system, such
as invariant natural killer T cells via lipid
antigen presentation, and they can produce a
vast array of cytokines in response to a variety
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or stimuli. Thus, B cell differentiation in the
presence of inflammation or following priming
by type 1 T helper (Th1) cells will produce high
levels of proinflammatory cytokines [43]. A
subset of B cells (Bregs) is capable of producing
high amounts of immunosuppressive IL-10 and
IL-15 [44]. Recent studies have shown that a
distinct set of immunoglobulin CD19?CD138?
plasma cells are the major B-cell subsets
producing these immunosuppressive cytokines
during autoimmune and infectious diseases
[45]. Similar to the situation regarding Tregs,
specific Bregs need to be developed and tested
before they can become a practicable treatment
option for RA patients; specifically, the subset
which produces the immunosuppressive
cytokines IL-10 and IL-15 needs to be
identified and tested for their efficacy in
therapy.
B Cell-Targeted Therapies
Rituximab, a B-cell depleting chimeric
monoclonal antibody against the CD20
protein, is a solid component of current
treatment options for RA patients. Two new
monoclonal antibodies against the CD20
antigen, ocrelizumab and ofatumomab, are
available but not yet licensed. Whether
ocrelizumab will be tested further as a possible
treatment for eliminating B cells in RA patients
remains at yet undetermined. Ofatumomab,
which targets a membrane proximal epitope
on the CD20 molecule, is distinct from other
CD20 antibodies in that it has been approved
for the treatment of chronic lymphocytic
leukemia (CLL) [46]. The results of a clinical
trial in RA patients [47] has been published, but
approval for the use of ofatumomab to treat RA
is still pending, awaiting the results of pivotal
Phase-III studies, long-term studies, and
head-to-head comparative studies with
rituximab (if possible).
A Bruton’s tyrosine kinase (BTK) inhibitor
has recently been licensed for patients suffering
from CLL. This BTK inhibitor, ibrutinib, may
also be of interest for evaluation in patients
with B-cell mediated autoimmune diseases [48].
The action of both tabalumab and atacicept
to target B-cell survival factors has been tested,
but only marginal therapeutic responses or no
clinical efficacy at all were observed in RA
patients [49, 50].
Based on data showing that Tregs are unable
to limit B-cell responses in RA patients, the FAS
pathway was identified as a possible novel target
for Treg-mediated suppression of B cells [51].
Attacking the CD22 surface molecule on B
cells by a sialic-acid binding
immunoglobulin-like lectin (siglec) has been
demonstrated to be a successful therapeutic
approach for the treatment of B-lymphoma
patients [52]. This new therapeutic option as
well as the new monoclonal antibodies
attacking the CD19 or CD319 molecules that
have been introduced successfully into the
treatment of plasmocytoma patients might
also be used in the future for treating patients
with B-cell autoimmune diseases like RA or SLE.
SMALL MOLECULES
Blocking Signaling Pathways
After two decades of often disappointing
research and development, kinase inhibitors
have ultimately found their way into the
treatment repertoire for RA [53, 54]. It has
been reported that the blocking of one or more
kinases leads to a modulation of the function of
different cellular structures, such as surface
receptors, signaling proteins, and the
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transcription of nuclear proteins, thereby
influencing the behavior of the affected cell
types. Tofacitinib, a drug of the Janus kinase
(JAK) inhibitor class, has been approved for the
treatment of RA [55–57]. Other kinase
inhibitors are still under investigation in
clinical trials, including baricitenib, which
blocks both JAC-1 and JAC-2, and is presently
being investigated in Phase-III trials. Baricitenib
has additionally been demonstrated to be safe
and clinically efficacious in RA patients who fail
to respond to TNF-blockers [58, 59]. A JAC-1
inhibitor, ABT-494, which has been found to be
effective for the treatment of refractory
moderate to severe RA in two Phase-II studies,
is also presently under clinical investigation
[60]. Some questions concerning kinase
inhibitor, however, remain unanswered:
Where is the place for kinase inhibitors in our
treatment repertoire: Can medications which
interfere with intracellular signaling pathways
be combined with other biologics? What is the
long-term safety profile of molecules blocking
intracellular signaling pathways?
Blocking the Proteasome
The proteasome inhibitor bortezomib, whose
mode of action is to induce an unfolded protein
response, has been approved for the treatment
of myeloma, suggesting that inhibition of the
immunoproteasome may also be an effective
treatment approach for antibody-mediated
autoimmune diseases.
Using the NZB/W mice model for SLE, a
research group from the University Hospital
Erlangen demonstrated that mice receiving
bortezomib survived for a period of[70 weeks
as compared to control animals who survived
50 to 60 weeks. Histology studies showed
normal kidney structures in the
bortezomib-treated animals, with depletion of
plasma cells producing antibodies to
double-stranded DNA. Even in animal models
of established diseases, there was significant
improvement in their clinical signs and
symptoms when bortezomib was given [61]. It
was shown that bortezomib specifically
eliminated the so-called long-lived plasma
cells in diseased organs and in the bone
marrow [62]. In a first open clinical trial,
bortezomib was demonstrated to be of clinical
value for those SLE patients who are refractory
to all other know treatment modalities [63].
Thus, bortezomib or other new proteasome
inhibitors which are less toxic could become a
true alternative for the treatment of RA patients
and other patients with pathogenic
autoantibodies.
CONCLUSION
These are exciting times for both patients and
treating physicians. New compounds are being
developed for treatment of RA patients and
patients with other autoimmune rheumatic
diseases based on the definition of new targets.
This is of specific interest for those patients who
are refractory to the currently available
biologics. In addition to identifying new
targets, researchers are exploring new avenues
for therapy, such as the use of bispecific
monoclonal antibodies, synerkines, or small
molecules interfering with different
intracellular signaling pathways. Cells like
leucocytes, monocytes, macrophages, and
synovial cells, including synovial fibroblasts,
might be defined as valuable targets for immune
intervention, including a possible
intra-articular application of biologics.
However, despite these new and exciting
treatment developments for RA, markers to
define patients who will respond to a given
biologic are still missing. Such markers will give
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provide the treating physician with a clue
regarding to the clinical course of the disease
and will improve the approach to
individualized medicine.
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